Bio-Techne Corporation and Halozyme Therapeutics, Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends in the Biotech Sector

In the ever-evolving biotech industry, understanding spending patterns is crucial for investors and stakeholders. Over the past decade, Bio-Techne Corporation has consistently increased its Selling, General, and Administrative (SG&A) expenses, reflecting a strategic expansion. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 500%, peaking at nearly $400 million in 2023. This growth underscores the company's commitment to scaling operations and enhancing market presence.

Conversely, Halozyme Therapeutics, Inc. exhibited a more volatile SG&A trajectory. While starting at a modest $36 million in 2014, their expenses saw a dramatic rise, reaching approximately $149 million by 2023. This represents a staggering 400% increase, highlighting Halozyme's aggressive investment in administrative capabilities and market strategies.

These trends offer a window into the strategic priorities of these biotech giants, with Bio-Techne focusing on steady growth and Halozyme on rapid expansion.